Teva receives FDA approval for schizophrenia treatment - stock jumps 5% in pre-market in New York

Teva announced FDA approval for WELTRUZA, a monthly subcutaneous injection treatment for schizophrenia. Clinical trials showed improvement in symptoms and functioning. The stock is up 5% in pre-market trading in New York.

Teva announced that the U.S. Food and Drug Administration (FDA) has approved WELTRUZA, an extended-release injectable suspension for the treatment of schizophrenia. This is a new, long-term treatment administered as a once-monthly subcutaneous injection for adults. Clinical trial results showed improvement in disease symptoms, a significant reduction in severity, and improvement in personal and social functioning. The stock is climbing 5% in pre-market trading in New York. Dr. Eric Hughes, Executive Vice President and Head of Global R&D at Teva, noted that the approval reflects patient-focused innovation and that WELTRUZA eliminates the need for post-injection monitoring, thereby addressing a significant barrier to treatment.